Innovative Age-Related Therapies Rejuvenate Bio specializes in gene therapies targeting chronic age-related diseases such as heart, metabolic, and kidney diseases, positioning it as a leader in the cutting-edge biotechnology space focused on reversing age-associated conditions.

Recent Funding Growth The company secured $4 million in recent funding, reflecting investor confidence in its transformative research and potential for expansion into new therapeutic areas and markets.

Strategic Partnerships Partnerships with leading Animal Health companies for gene therapy development demonstrate opportunities to expand into veterinary markets, presenting additional revenue streams and cross-sector collaboration opportunities.

Clinical Development Milestones Rejuvenate Bio has launched preclinical efficacy data for RJB-0402 and is advancing its gene therapy pipeline, signaling readiness for potential clinical trial partnerships and early adoption by healthcare providers.

Growth and Expertise With an employee base of up to 50 and strategic hires in medical and scientific leadership, the company is positioned for accelerated growth, offering opportunities to collaborate with specialized talent and leverage its evolving scientific capabilities.